{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:45:48Z","timestamp":1748972748308,"version":"3.40.4"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,5,21]]},"abstract":"<jats:p>The era of direct acting antivirals has revolutionised the management of chronic hepatitis C infection and improved patient outcomes. The optimal management of patients who require liver transplantation remains a matter of ongoing discussion. Treatment in the post-transplantation setting may be complicated by significant drug\u2013drug interactions between antiviral agents and standard immune suppressive treatment regimens. We describe what we believe to be the first reported case of a patient successfully treated for CHC with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir, while taking sirolimus following liver transplantation.<\/jats:p>","DOI":"10.1136\/bcr-2018-224664","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T05:55:15Z","timestamp":1528350915000},"page":"bcr-2018-224664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C"],"prefix":"10.1136","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-4066","authenticated-orcid":false,"given":"Grace Elizabeth","family":"Dolman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Selby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T","family":"Gelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27770"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28446"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/tri.12910","article-title":"Real-world experience with daclatasvir plus sofosbuvir\u00b1ribavirin for post-liver transplant HCV recurrence and severe liver disease","volume":"30","author":"Herzer","year":"2017","journal-title":"Transpl Int"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/apt.13790","article-title":"Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir \u00b1 ribavirin in hepatitis C: AMBER study","volume":"44","author":"Flisiak","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13111"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.8","unstructured":"Preston CE . Interactions stockley\u2019s drug. London: Pharmaceutical Press, 2015."},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.9","unstructured":"Liverpool Uo. Hep drug interactions. 2017 www.hepdruginteractions.org"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.10","unstructured":"Group BW. UK guidelines for kidney and pancreas transplantation in patients with HIV. London: British Transplantation Society, 2015."},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00706.x"},{"key":"2025042703494862000_2018.jun06_1.bcr-2018-224664.12","unstructured":"British Medical Association & Royal Pharmaceutical Society. British national formulary. 2017. London: British Medical Association & Royal Pharmaceutical Society."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-224664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:49:53Z","timestamp":1745750993000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-224664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":12,"alternative-id":["10.1136\/bcr-2018-224664"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-224664","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,6,6]]}}}